Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novaferon versus lopinavir/ritonavir or their combination for viral clearance in hospitalized adults with COVID-19
ChiCTR2000029496Phase 4Recruiting
- Sponsor
- The First Hospital of Changsha
- Start
- Jan 2020
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of novaferon and lopinavir + ritonavir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by The First Hospital of Changsha. Primary endpoint: Novel coronavirus nucleic acid clearance rate. Started Jan 2020; status: recruiting.
02
Drugs
novaferonlopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029496.